| 000 | 01438 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517150022.0 | ||
| 264 | 0 | _c20180529 | |
| 008 | 201805s 0 0 eng d | ||
| 022 | _a1938-0666 | ||
| 024 | 7 |
_a10.1016/j.clbc.2017.03.003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVidal, Gregory A | |
| 245 | 0 | 0 |
_aPhase I Trial of Everolimus and Capecitabine in Metastatic HER2 _h[electronic resource] |
| 260 |
_bClinical breast cancer _c10 2017 |
||
| 300 |
_a418-426 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCapecitabine _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEverolimus _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aChen, Mary | |
| 700 | 1 | _aSheth, Shruti | |
| 700 | 1 | _aSvahn, Tiffany | |
| 700 | 1 | _aGuardino, Ellie | |
| 773 | 0 |
_tClinical breast cancer _gvol. 17 _gno. 6 _gp. 418-426 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clbc.2017.03.003 _zAvailable from publisher's website |
| 999 |
_c27057592 _d27057592 |
||